본문으로 건너뛰기
← 뒤로

Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.

증례보고 1/5 보강
Internal medicine (Tokyo, Japan) 📖 저널 OA 63.8% 2024: 6/6 OA 2025: 37/56 OA 2026: 50/84 OA 2024~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
chemotherapy combined with durvalumab and tremelimumab (POSEIDON regimen)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
They thereafter achieved excellent clinical outcomes, including complete and partial responses, with sustained benefits. The POSEIDON regimen may represent a potent therapeutic option for this rare patient population with multiple negative prognostic factors.

Ichikawa T, Kudo K, Takigawa Y, Osedo T, Sasano Y, Kitano T, Nishimura J, Watanabe H, Sato K, Fujiwara K

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Pulmonary sarcomatoid carcinoma (PSC) and Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are poor prognostic factors in non-small cell lung cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Ichikawa T, Kudo K, et al. (2026). Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6660-25
MLA Ichikawa T, et al.. "Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.." Internal medicine (Tokyo, Japan), 2026.
PMID 41850829 ↗

Abstract

Pulmonary sarcomatoid carcinoma (PSC) and Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are poor prognostic factors in non-small cell lung cancer. We report two cases of metastatic KRAS G12C-positive PSC in men (aged 69 and 66 years). Both patients were treated with chemotherapy combined with durvalumab and tremelimumab (POSEIDON regimen). They thereafter achieved excellent clinical outcomes, including complete and partial responses, with sustained benefits. The POSEIDON regimen may represent a potent therapeutic option for this rare patient population with multiple negative prognostic factors.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (4)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반